Literature DB >> 1962150

Molecular nature and possible presence of a membranous glycan-phosphatidylinositol anchor of CA125 antigen.

A Nagata1, N Hirota, T Sakai, M Fujimoto, T Komoda.   

Abstract

The molecular nature and possible presence of a glycan-phosphatidylinositol anchor (GPI-anchor) in CA125 molecules was investigated. Serial lectin affinity chromatography and N- or O-glycanase treatment to reduce antigenicity showed that CA125 contained certain N- and O-glycosylated sugar chains in the molecule, like a glycoprotein. CA125 released from ovarian cancer tissues increased time-dependently following phosphatidylinositol-specific phospholipase C (PI-PLC) treatment, concomitant with the release of tissue-unspecific alkaline phosphatase. Western blotting of CA125 treated by PI-PLC showed a single band of 90 kD instead of the 162- and 76-kD bands of the native antigen. Further, ovarian cancer tissues subjected to PI-PLC treatment lost the immunohistochemical localization of CA125 with OC125 antibody. Consequently, it is strongly suggested that CA125 is a glycoprotein that has both N- and O-linked sugar chains and a membranous GPI-anchoring moiety, and further, that its 90-kD form is the antigen without the GPI-anchor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1962150     DOI: 10.1159/000217716

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  7 in total

1.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

Review 2.  Glycoprotein disease markers and single protein-omics.

Authors:  Kevin Chandler; Radoslav Goldman
Journal:  Mol Cell Proteomics       Date:  2013-02-11       Impact factor: 5.911

3.  MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

Authors:  Panagiota Giannakouros; Marina Comamala; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

4.  MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.

Authors:  Ying Wang; Dong-Joo Cheon; Zhen Lu; Sheena L Cunningham; Chun-Ming Chen; Robert Z Luo; Deyin Xing; Sandra Orsulic; Robert C Bast; Richard R Behringer
Journal:  Differentiation       Date:  2008-07-02       Impact factor: 3.880

5.  Investigations with O-linked protein glycosylations by matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry.

Authors:  Taufika Islam Williams; Diana A Saggese; Kristina L Toups; Jennifer L Frahm; Hyun Joo An; Bensheng Li; Carlito B Lebrilla; David C Muddiman
Journal:  J Mass Spectrom       Date:  2008-09       Impact factor: 1.982

6.  Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.

Authors:  M Comamala; M Pinard; C Thériault; I Matte; A Albert; M Boivin; J Beaudin; A Piché; C Rancourt
Journal:  Br J Cancer       Date:  2011-02-15       Impact factor: 7.640

Review 7.  Deciphering the molecular nature of ovarian cancer biomarker CA125.

Authors:  Florian Weiland; Karina Martin; Martin K Oehler; Peter Hoffmann
Journal:  Int J Mol Sci       Date:  2012-08-22       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.